

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

EDWARDS LIFESCIENCES CORPORATION AND  
EDWARDS LIFESCIENCES LLC,  
Petitioner,

v.

COLIBRI HEART VALVE LLC,  
Patent Owner.

---

IPR2021-00775  
Patent 9,125,739 B2

---

Before ERICA A. FRANKLIN, JAMES A. TARTAL, and  
ERIC C. JESCHKE, *Administrative Patent Judges*.

TARTAL, *Administrative Patent Judge*.

DECISION  
Granting Institution of *Inter Partes* Review  
35 U.S.C. § 314  
Granting Motion for Joinder  
35 U.S.C. § 315(c); 37 C.F.R. § 42.122

## I. INTRODUCTION

On April 6, 2021, Edwards Lifesciences Corporation and Edwards Lifesciences LLC (“Petitioner” or “Edwards”) filed a Petition pursuant to 35 U.S.C. §§ 311–319 requesting an *inter partes* review of claims 1–5 (“the Challenged Claims”) of U.S. Patent No. 9,125,739 B2 (Ex. 1001, “the ’739 patent”). Paper 2 (“Pet.”). Concurrently, Petitioner filed a Motion for Joinder seeking to join *Medtronic CoreValve LLC v. Colibri Heart Valve LLC*, IPR2020-01454 (the “Medtronic IPR”). Paper 3 (the “Motion” or “Mot.”). *Inter partes* review was instituted in the Medtronic IPR on March 10, 2021. Medtronic IPR, Paper 11 (PTAB March 10, 2021) (the “Medtronic IPR Institution Decision”). The Petition is substantively identical to the petition on which *inter partes* review was instituted in the Medtronic IPR. *See* Ex. 1025 (comparison of the Petition to the petition in the Medtronic IPR). Colibri Heart Valve LLC (“Patent Owner”) did not file a preliminary response to the Petition or an opposition to the Motion.

We have authority to determine whether to institute an *inter partes* review. 35 U.S.C. § 314(b) (2018); 37 C.F.R. § 42.4(a) (2020). An *inter partes* review may not be instituted “unless . . . the information presented in the petition . . . shows that there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314(a). Upon consideration of the Petition and the evidence of record, we conclude that the information presented shows a reasonable likelihood that Petitioner would prevail in showing the unpatentability of at least one of the Challenged Claims. Accordingly, we authorize an *inter partes* review to be instituted as to the Challenged Claims of the ’739 patent on the grounds raised in the Petition. This is not a final decision as to patentability of claims for which *inter partes* review is

instituted. Any final decision will be based on the record, as fully developed during trial. We also grant the unopposed Motion and join Petitioner to the Medtronic IPR (IPR2020-01454).

## II. BACKGROUND

### A. *The '739 Patent*

The '739 patent, titled “Percutaneous Replacement Heart Valve and a Deliver and Implantation System,” issued September 8, 2015, from Application No. 14/253,650 (“the '650 Application”), filed April 15, 2014. Ex. 1001, codes (21), (22), (45), (54). The replacement heart valve device described by the '739 patent “comprises a stent made of stainless steel or self-expanding nitinol and a completely newly designed artificial biological tissue valve disposed within the inner space of the stent.” *Id.* at 4:64–5:1.

Figure 5 of the '739 patent is reproduced below.




FIG.5

Figure 5 illustrates a side view of a replacement heart valve device mounted within a self-expanding stent in the expanded position. Ex. 1001, 6:31–34. “The replacement heart valve device comprises a stent member 100 and a flexible valve means 200.” *Id.* at 6:55–57. “The stent member 100 includes a length of wire 110 formed in a closed zigzag configuration.” *Id.* at 7:32–33. The stent member may be a meshwork of nitinol wire formed into a

tubular structure that “flares markedly at both ends in a trumpet-like configuration.” *Id.* at 7:55–63. The “trumpet-like configuration” is not illustrated in Figure 5, or in any other figure of the ’739 patent.

The valve means comprises “a generally tubular portion” and, “preferably, a peripheral upstanding cusp or leaflet portion.” *Id.* at 6:61–64. The valve means is “flexible, compressible, host-compatible, and non-thrombogenic.” *Id.* at 8:27–28. It may be made from various materials, preferably mammal pericardium tissue. *Id.* at 8:28–35. The cusp or leaflet portion of the valve means is generally tubular in shape and comprises two to four leaflets. *Id.* at 7:5–8. The cusp or leaflet portion of the valve means is “formed by folding of the pericardium material used to create the valve.” *Id.* at 8:44–46. “The starting material is preferably a flat dry sheet, which can be rectangular or other shaped.” *Id.* at 8:47–49. The cusps/leaflets “open in response to blood flow in one direction and close in response to blood flow in the opposite direction.” *Id.* at 8:49–51.

Figure 8 of the '739 patent is reproduced below.




FIG. 8

Figure 8 illustrates the “delivery and implantation system of the replacement artificial heart valve,” including “flexible catheter 400 which may be inserted into a vessel of the patient and moved within that vessel.” *Id.* at 11:40–44. The '739 patent further explains as follows:

The distal end 410 of the catheter 400, which is hollow and carries the replacement heart valve device of the present invention in its collapsed configuration, is guided to a site where it is desired to implant the replacement heart valve. The catheter has a pusher member 420 disposed within the catheter lumen 430 and extending from the proximal end 440 of the catheter to the hollow section at the distal end 410 of the catheter. Once the distal end 410 of the catheter is positioned as desired, the pusher mechanism 420 is activated and the distal portion of the replacement heart valve device is pushed out of the catheter and the stent member 100 partially expands. In this position the stent member 100 is restrained so that it doesn't pop out and is held for controlled release, with the potential that the replacement heart

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.